Morgan Stanley has named Spirax its preferred choice within UK industrials, upgrading the stock to an "overweight" rating and establishing a price target of 8,500p. The broker's valuation blends a market multiple and a discounted cash flow framework, reflecting both a forward-looking earnings multiple and a long-term cash-flow view.
Specifically, the 8,500p target is derived from the average of two approaches: an applied 18x enterprise value to 2027 EBIT multiple and a discounted cash flow model that assumes a 3% perpetual growth rate and a 7% weighted average cost of capital. Morgan Stanley pointed to Spirax's improving organic growth outlook and an expected recovery in margins as central to its constructive stance. The broker also flagged the firm's exposure to the Watson-Marlow business - described as higher-margin - as a supportive factor for profitability.
Alongside the overweight call on Spirax, Morgan Stanley left unchanged its "equal-weight" recommendations for peers Halma, Weir and Rotork, indicating a differentiated view across the sector rather than a broad sector upgrade.
The broker outlined upside and downside scenarios tied to the investment case. Upside risks include continued robust expansion at Watson-Marlow and a wider recovery in industrial production, both of which would support revenue and margin trajectories. Conversely, downside pressures noted by Morgan Stanley include currency movements - specifically a stronger pound versus the U.S. dollar or euro - and cost pressures from imported materials, driven by base metal prices and purchased components. The broker also flagged the potential for weaker-than-expected performance of intellectual property in Asia and the United States as a downside risk to the forecast.
The analysis and the price target reflect Morgan Stanley's explicit modeling assumptions and risk considerations, rather than an assertion of guaranteed outcomes. Investors and market participants should note that the broker's outlook is contingent on the realization of the growth and margin scenarios it outlines, and on the absence of the adverse developments it identifies.
Valuation framework applied by Morgan Stanley
- 18x applied multiple on 2027 EV/EBIT (one leg of the valuation)
- Discounted cash flow with a 3% perpetual growth rate and a 7% WACC (second leg)
These two methods are averaged to produce the 8,500p target cited by the broker.